Literature DB >> 32071429

The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia.

Colin D Godwin1,2, George S Laszlo1, Brent L Wood3, Colin E Correnti1, Olivia M Bates1, Eliotte E Garling1, Zhengwei J Mao3, Mary E Beddoe1, Margaret C Lunn1, Olivier Humbert1, Hans-Peter Kiem1,4,5, Roland B Walter6,7,8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32071429      PMCID： PMC7431376          DOI： 10.1038/s41375-020-0755-7

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Pseudogene-Mediated Gene Conversion After CRISPR-Cas9 Editing Demonstrated by Partial CD33 Conversion with SIGLEC22P.

Authors:  Benjamin C Shaw; Steven Estus
Journal:  CRISPR J       Date:  2021-09-23

2.  T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.

Authors:  Sayed Shahabuddin Hoseini; Mallika Vadlamudi; Madelyn Espinosa-Cotton; Hoa Tran; Yi Feng; Hong-Fen Guo; Hong Xu; Irene Cheung; Nai-Kong V Cheung
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 3.  The role of innate immune genes in Alzheimer's disease.

Authors:  Ana Griciuc; Rudolph E Tanzi
Journal:  Curr Opin Neurol       Date:  2021-04-01       Impact factor: 6.283

4.  The CD33 short isoform is a gain-of-function variant that enhances Aβ1-42 phagocytosis in microglia.

Authors:  Abhishek Bhattacherjee; Jaesoo Jung; Sameera Zia; Madelene Ho; Ghazaleh Eskandari-Sedighi; Chris D St Laurent; Kelli A McCord; Arjun Bains; Gaurav Sidhu; Susmita Sarkar; Jason R Plemel; Matthew S Macauley
Journal:  Mol Neurodegener       Date:  2021-03-25       Impact factor: 14.195
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.